Board of Directors

Dr. Goodman is our Co-founder and Chairman of our board of directors. He served as Executive Chairman from March 2015 to July 2024. He co-founded and has served as a Managing Partner of venBio Partners since March 2010. Dr. Goodman founded Labrys, a biopharmaceutical company acquired by Teva, where he served as Chairman and as a member of the board of directors from December 2012 to June 2014. He also founded Pfizer’s Biotherapeutics and Bioinnovation Center, where he served as President and a member of Pfizer’s Executive Leadership Team from October 2007 until May 2009. He co-founded Renovis, a biopharmaceutical company acquired by Evotec, where he served as President, Chief Executive Officer and a director from September 2001 to October 2007. He is a former tenured biology professor at both Stanford University and the University of California, Berkeley, the co-founder of UC Berkeley’s Wills Neuroscience Institute, an investigator with the Howard Hughes Medical Institute and currently is an adjunct professor at UC Berkeley. Dr. Goodman is a member of the U.S. National Academy of Sciences, the American Academy of Arts & Sciences and the American Philosophical Society, and a recipient of the 2020 Gruber Neuroscience Prize. He currently serves as chairman and as a member of the board of directors of several privately held biotechnology companies. Dr. Goodman holds a Bachelor of Science degree in biology from Stanford University and a Ph.D. in neurobiology from UC Berkeley. He was a postdoctoral fellow at the University of California, San Diego.

Ms. Hemrajani has served as a member of our board of directors since April 2020. She currently serves as a director at MaxCyte and BioAge Labs. She has previously served as Chief Executive Officer and Director of Jiya Acquisition Corporation, a Special Purpose Acquisition Company, and President and Chief Executive Officer of Aravive, Inc., a clinical-stage biotechnology company, Chief Operating Officer and Chief Financial Officer of Arcus Biosciences, a biotechnology company, Chief Operating Officer of FLX Bio, Inc. (now RAPT Therapeutics, Inc.), a biotechnology company and Chief Financial Officer and Senior Vice President of Business and Financial Operations at 3-V Biosciences, Inc. (now Sagimet Biosciences, Inc.), a biotechnology company. Ms. Hemrajani was also Vice President, Head of Licensing and M&A at Onyx Pharmaceuticals (acquired by Amgen) and Vice President of Business Development at Exelixis. She started her career in healthcare investment banking at Credit Suisse First Boston and Lehman Brothers. She holds a Bachelor of Science degree in economics and computer science from the University of Michigan and an MBA from the Kellogg Graduate School of Management at Northwestern University.

Mr. Garland has served as a member of our board of directors since November 2022. He served as the Chief Executive Officer of PACT Pharma, Inc., an immuno-oncology company, from March 2021 to February 2023. Mr. Garland remains a member of PACT’s board of directors. He was formerly the Chief Executive Officer of Portola Pharmaceuticals, which was acquired by Alexion in 2020. At Portola, he led the company through the commercial launch of Andrexxa®, a novel reversal agent for factor Xa inhibitors. Before joining Portola, Mr. Garland held leadership roles at multiple pharmaceutical and biotechnology companies. At Relypsa, he served first as Chief Commercial Officer, then as President overseeing the U.S. commercial launch of Veltassa® for the treatment of hyperkalemia. Prior to Relypsa, Mr. Garland spent three years as Chief Commercial Officer at Exelixis, where he built the commercial organization for the company’s launch of cabozantinib in medullary thyroid cancer. He also spent nine years at Genentech, where he led the commercial franchises for two multibillion-dollar cancer therapies – Avastin® and Rituxan®. Mr. Garland is also a member of the board of directors of Day One Biopharmaceuticals and Calithera Biosciences, and formerly was a board member of Karyopharm Therapeutics. Mr. Garland received a Bachelor of Science degree from California Polytechnic State University, San Luis Obispo and an MBA from the Fuqua School of Business at Duke University.

Mr. Lettmann has served as our Chief Executive Officer since September 2023 and as a member of our board of directors since April 2020. He previously served as a member of our board of directors from March 2015 to May 2017. Previously, Mr. Lettmann was a General Partner of Lightstone Ventures from March 2012 to July 2023 and a Partner at Morgenthaler Ventures, a venture capital and private equity firm, since June 2009. He previously served as Chief Executive Officer of Promedior Inc., a biotechnology company acquired by Roche, from January 2019 to February 2020 and as Vice President at Split Rock Partners, a venture capital firm, from June 2006 to June 2009. Mr. Lettmann has been a member of the board of directors of several public and privately held companies, including Ra Pharmaceuticals, a clinical-stage pharmaceutical company acquired by UCB. Mr. Lettmann holds a Bachelor of Arts degree in psychology from the University of Iowa and an MBA from the University of Michigan’s Ross School of Business.

Dr. Klencke has served as a member of our board of directors since January 2025. She currently serves as an independent board director of Xencor, TScan Therapeutics and Immune-Onc Therapeutics. Dr. Klencke has over 30 years of experience in patient care, academic and scientific research and clinical drug development in hematology and oncology. She has served in various executive leadership roles at a range of small, mid-sized, and large biotech companies including Sierra Oncology, Inc. (acquired by GlaxoSmithKline for $1.9B), Onyx Pharmaceuticals (acquired by Amgen for $10.4B) and Genentech, a member of the Roche Group. Prior to entering the biotechnology industry, Dr. Klencke served as an Assistant Clinical Professor of Medicine, Division of Hematology and Oncology, at the University of California, San Francisco, where she previously completed her training in hematology, oncology and internal medicine. She holds a Bachelor of Science degree from Indiana University and an M.D. from the University of California, Davis.

Dr. Takimoto has served as a member of our board of directors since January 2025. He currently serves as Global Chief Medical Officer at the START Center for Cancer Research. Dr. Takimoto has over 30 years of experience in oncology and pharmacology through a distinguished career across academia, industry and public service. He previously served as Chief Medical Officer at IGM Biosciences and Forty Seven, Inc., the latter through its acquisition by Gilead for $4.9 billion, and Senior Vice President of Oncology at Gilead Sciences, Inc. Prior to these positions, he held roles of increasing responsibility in oncology drug development at Janssen/Johnson & Johnson. Dr. Takimoto has held academic positions at the University of Texas Health Science Center at San Antonio, the National Cancer Institute and the Uniformed Services University of the Health Sciences, and he has served as a Commissioned Officer in the U.S. Public Health Service. Dr. Takimoto completed his internship and residency in internal medicine at the University of California, San Francisco, and a fellowship in oncology at the National Cancer Institute. He received a Bachelor of Science degree in chemistry from Stanford University, a Ph.D. in pharmacology from Yale University and an M.D. from Yale University School of Medicine.